Ask AI
CAR T Bridging in MM

CE / CME

Optimizing Bridging Therapy: Selection and Timing to Support CAR T-Cell Success in MM

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 30, 2025

Expiration: April 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 70-year-old patient with multiple myeloma (MM) is being evaluated for BCMA-directed CAR T-cell therapy, with an anticipated manufacturing wait time of approximately 5 weeks. He experienced his first relapse after initial therapy with daratumumab/lenalidomide/dexamethasone. His second-line regimen, pomalidomide/bortezomib/dexamethasone, was discontinued after only 3 months because of disease progression. He currently has a high disease burden and is refractory to lenalidomide.

Which of the following would be the most appropriate choice for bridging therapy for this patient?

2.

A 62-year-old patient with relapsed/refractory MM is referred for BCMA-directed CAR T-cell therapy after 4 prior lines of therapy. The patient is penta-drug refractory (including to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody) and has a high disease burden with rapidly progressive symptoms. Manufacturing is expected to take approximately 4-5 weeks.

Which of the following would be the most appropriate choice for bridging therapy for this patient?